Clinical Trials Browser

INDUSTRY × Lymphoma, Non-Hodgkin × ofatumumab × Clear all

NCT01294579 2018-08-09

Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL)

Phase 2 Completed

49 enrolled 13 charts

Lymphoma, Non-Hodgkin, Recurrence

NCT01200589 2018-05-16

HOMER

Phase 3 Terminated

438 enrolled 14 charts

Lymphoma, Non-Hodgkin

NCT00092274 2015-04-21

Study of HuMax-CD20, a New Drug to Treat Early Stage Non-Hodgkin´s Follicular Lymphoma

Phase 1/2 Withdrawn

Lymphoma, Follicular, Lymphoma, Non-Hodgkin

NCT00823719 2013-03-12

Phase II Study of Ofatumumab Plus Ifosfamide, Carboplatin, Etoposide (ICE) or Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Phase 2 Completed

61 enrolled 25 charts

Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT01108341 2012-08-28

Study to Evaluate the Efficacy and Safety of Treatment With Bendamustine in Combination With Ofatumumab in Previously Untreated Patients With Indolent B-Cell Non-Hodgkin's Lymphoma (NHL)

Phase 2 Completed

50 enrolled 10 charts

Lymphoma, Non-Hodgkin